Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9487979 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBHTTKMT2AMAPT | |
| SCHEMBL17828189 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBHTTKMT2ACARM1 | |
| SCHEMBL14375246 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBHTTKMT2AMEN1 | |
| SCHEMBL8485788 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBHTTKMT2ATP53 | |
| SCHEMBL1174392 | 0.84 | — | — | |
| SCHEMBL4489670 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2AMAPTTP53L3MBTL1 | |
| SCHEMBL25755513 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBHTTKMT2AMAPT | |
| SCHEMBL4263555 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2POLBHTTKMT2AMAPT | |
| SCHEMBL8554604 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2POLBHTTKMT2AMAPT | |
| SCHEMBL13601396 | 0.82 | POLB (0.54) | SMN1; SMN2POLBHTTKMT2ACARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20200247789-A2 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUCTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2020-01-28 | — | — | US | disclosed |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| CN-103980204-B | Ionic liquid-catalyzed amine and α, β-unsaturated electron deficiency receptor method | TAIZHOU UNIVERSITY (CN) | 2016-03-30 | — | — | CN | disclosed |
| CN-103980204-A | Method for catalyzing amines and alpha, beta-unsaturated electron-deficient acceptors by ionic liquid | UNIV TAIZHOU | 2014-08-13 | — | — | CN | disclosed |
| EP-1228070-B1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| EP-1228070-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001029042-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885POLB 1106/4885HTT 352/4885 |
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | SGK3, SGK2, GDI2 | SMN1; SMN2 1754/4885POLB 2571/4885HTT 1374/4885 |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | SMN1; SMN2 4132/4885POLB 874/4885HTT 351/4885 |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885POLB 1106/4885HTT 352/4885 |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | SGK3, SGK2, GDI2 | SMN1; SMN2 1754/4885POLB 2571/4885HTT 1374/4885 |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885POLB 1106/4885HTT 352/4885 |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | SMN1; SMN2 4132/4885POLB 874/4885HTT 351/4885 |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885POLB 1106/4885HTT 352/4885 |
| US-20200247789-A2 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885POLB 1106/4885HTT 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.